VEGFA and neoplasm: Finally, in another experiment the in vivo anti-tumor activity of an anti-angiogenic strategy that prevents VEGF action by blocking the VEGR receptor (VEGFr) was examined using the rat anti-murine VEGFr monoclonal antibody (DC101).